Related Experiment Videos
Ofloxacin clinical pharmacokinetics
K C Lamp1, E M Bailey, M J Rybak
1Department of Pharmacy Practice, College of Pharmacy and Allied Health Professions, School of Medicine, Wayne State University, Detroit, Michigan.
Clinical Pharmacokinetics
|January 1, 1992
Summary
Ofloxacin, a novel fluoroquinolone, shows broad-spectrum activity and may reduce resistance development in Staphylococcus aureus. Further clinical studies are needed to fully assess its therapeutic potential.
Area of Science:
- Pharmacology
- Microbiology
- Drug Development
Background:
- Ofloxacin is a new fluoroquinolone antibiotic.
- It exhibits activity against various pathogens including Chlamydia trachomatis, Mycobacterium spp., Mycoplasma spp., and Legionella pneumophila.
- Potential for reduced resistance development compared to existing fluoroquinolones due to additional mechanisms of action.
Purpose of the Study:
- To evaluate the pharmacological properties and potential therapeutic advantages of ofloxacin.
- To compare ofloxacin's pharmacokinetic profile with other fluoroquinolones.
- To assess potential drug interactions of ofloxacin.
Main Methods:
- Pharmacokinetic analysis of ofloxacin following oral administration.
- Comparison of elimination pathways with other quinolone antibiotics.
- Assessment of potential interactions with commonly co-administered drugs like theophylline.
Main Results:
- Ofloxacin demonstrates high bioavailability (95-100%) with peak serum concentrations of 2-3 mg/L after a 400mg dose.
- Average half-life is 5-8 hours, with elimination primarily dependent on renal clearance.
- Ofloxacin appears to have fewer pharmacokinetic interactions with drugs like theophylline compared to ciprofloxacin and enoxacin.
Conclusions:
- Ofloxacin possesses favorable pharmacokinetic properties and a broad spectrum of activity.
- Its unique mechanisms may offer advantages in combating fluoroquinolone resistance.
- Ofloxacin represents a viable therapeutic alternative to current fluoroquinolone antibiotics, though further clinical evaluation is warranted.